Flat first quarter for Eisai
This article was originally published in Scrip
Executive Summary
Despite a rise in global sales of the Alzheimer's disease therapy Aricept (donepezil), Eisai's net sales in the first quarter to June 30th slipped by around 1% to ¥194.7 billion ($2.05 billion), hit by currency effects and weakness for its other mainstay product, Aciphex/Pariet (rabeprazole).